Patents by Inventor Kenneth Russell Walder
Kenneth Russell Walder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10172837Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: GrantFiled: September 26, 2016Date of Patent: January 8, 2019Assignee: Naia Metabolic, Inc.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Publication number: 20170079960Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: ApplicationFiled: September 26, 2016Publication date: March 23, 2017Inventors: Gregory Royce COLLIER, Kenneth Russell WALDER, James Alexander CAMPBELL, Juan-Carlos MOLERO-NAVAJAS, Nicky KONSTANTOPOULOS, Guy Yeoman KRIPPNER
-
Patent number: 9452148Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: GrantFiled: May 31, 2013Date of Patent: September 27, 2016Assignee: Verva Pharmaceuticals LtdInventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Publication number: 20140011848Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: ApplicationFiled: May 31, 2013Publication date: January 9, 2014Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Patent number: 8455432Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: GrantFiled: January 25, 2008Date of Patent: June 4, 2013Assignee: Verva Pharmaceuticals Ltd.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Publication number: 20110112167Abstract: The present invention relates to diagnostic and therapeutic methods in relation to diabetic complications, such as blindness, nephropathy and cardiovascular disease, and inflammatory conditions, such as angina, arthritis, empyema pharyngitis and urinary tract infection. Diagnostic methods involve screening for up regulated expression of decor (Den) or thioredoxin-like protein 19 (TLP 19). Therapeutic methods involve modulation of expression or activity o Den or TLP 19. The invention also relates to screening methods for identifying functional signal sequences to screen for secreted, membrane-bound and exported proteins and cell surface receptors.Type: ApplicationFiled: May 17, 2006Publication date: May 12, 2011Applicant: AUTOGEN RESEARCH PTY LTDInventors: Gregory Royce Collier, Kenneth Russell Walder, Janine Susan McMillan, David Harry Segal, Kelly Fiona Windmill, Kristy Ann Bolton
-
Publication number: 20110003740Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: ApplicationFiled: January 25, 2008Publication date: January 6, 2011Applicant: VERVA PHARMACEUTICALS LTD.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Publication number: 20090143571Abstract: The present invention relates generally to nucleic acid molecules encoding proteins associated with the modulation of obesity, diabetes and/or metabolic energy levels. More particularly, the present invention is directed to nucleic acid molecules and the recombinant and purified proteins encoded thereby and their use in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid molecules and proteins and their derivatives, homologs, analogs, chemical equivalents and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance.Type: ApplicationFiled: August 15, 2008Publication date: June 4, 2009Applicant: AUTOGEN RESEARCH PTY LTDInventors: Gregory Collier, Paul Zev Zimmet, Kenneth Russell Walder, Kelly Fiona Windmill, Janine Susan McMillan
-
Publication number: 20080146502Abstract: The invention relates generally to a method for modulating the sensation of satiety perception and to agents useful for same. Such agents are useful in modulating, controlling or otherwise affecting inter alia obesity, anorexia, weight maintenance, metabolic energy levels and/or inflammatory conditions in a subject. More particularly, the invention identifies molecules which interact with ion channels thereby modulating the perception of satiety. The invention contemplates, therefore, a method for modulating the perception of gastric distension by the administration of agents which control the activation or inhibition of mechanoreceptors. The invention further provides compositions comprising these agents and methods of treatment using same. In one embodiment, the invention permits modulation of perception of gastric distension by the administration of agents which control the activation of mechanoreceptors associated with mechanical stretch.Type: ApplicationFiled: February 23, 2007Publication date: June 19, 2008Applicant: Autogen Research Pty Ltd.Inventors: Gregory Royce Collier, Kenneth Russell Walder
-
Publication number: 20080105961Abstract: Identification of molecules which modulate inter alia obesity, anorexia, weight maintenance, inflammation and/or metabolic energy levels in a subject are described which particularly relate to a protein molecule called “FIT”, previously known as “AGT-121”. Ligands of “FIT” as well as antagonists of “FIT”-ligand interaction are proposed to modulate inter alia obesity, anorexia, weight maintenance, inflammation and/or metabolic energy levels in a subject. Methods of treatment and prophylaxis and pharmaceutical compositions useful in modulating inter alia obesity, anorexia, weight maintenance, inflammation and/or metabolic energy levels are also provided.Type: ApplicationFiled: March 16, 2005Publication date: May 8, 2008Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Leonard Trevaskis, Janine Susan McMillan, Lyndal Jane Bayles
-
Publication number: 20020169287Abstract: The present invention relates generally to nucleic acid molecules encoding proteins associated with the modulation of obesity, diabetes and/or metabolic energy levels. More particularly, the present invention is directed to nucleic acid molecules and the recombinant and purified proteins encoded thereby and their use in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid molecules and proteins and their derivatives, homologs, analogs, chemical equivalents and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance.Type: ApplicationFiled: December 31, 2001Publication date: November 14, 2002Applicant: AUTOGEN RESEARCH PTY LTD.Inventors: Gregory Collier, Paul Zev Zimmet, Kenneth Russell Walder, Kelly Fiona Windmill, Janine Susan McMillan